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Introduction 49
The End TB Strategy approved by the World Health Assembly in May 2014 aims to end the global 50 tuberculosis (TB) epidemic in line with the Sustainable Development Goals (SDGs) by 2030, with the 51 targets of a 90% reduction in TB mortality, a 80% decline in TB incidence, and no TB-affected household 52 experiencing catastrophic costs due to TB 1 . The strategy relies on three fundamental pillars, including 53 "intensified research and innovation" 2 . Promoting research across its entire spectrum (including basic 54 science, clinical, epidemiological, health systems, and operational/implementation research (OR/IR)) is 55 critical to maximizing the impact on TB reduction strategies in all, especially in vulnerable and high risk 56 populations who have higher risks of TB infection and disease, as well as poor treatment outcomes. 57
As described in previous articles within this series, migrants are often an especially vulnerable population 58 due to the inherent risk of acquiring TB in high-and medium-burden countries, but also due to migration 59 specific determinants 3 that affect individuals in even low-burden countries. The first paper of the present 60
State of the Art series reviewed how migrants should be considered as a special vulnerable group within 61 the frame of the WHO End TB Strategy 4 . Growing surveillance data demonstrates the changing patterns 62 of TB incidence due in part to migration flows 3, 5 . This last paper of the series builds upon previous articles 63 in describing critical evidence gaps in the current knowledge of migration related TB issues that make 64 migration-inclusive research a priority for TB prevention and care. The intention of this paper is not to 65 present a prescriptive and comprehensive research agenda for TB in migrants, but to describe a systematic 66 approach to establishing migrant-inclusive TB research agendas and to provide pragmatic considerations 67 for operationalizing such agendas. 68
Development of a conceptual framework for identifying evidence gaps and research priorities 69 1) Consideration of the general TB determinants (biomedical, social, and structural) within migrant 92
communities. 93
2) Consideration of the full migration pathway, from the country of origin, along the transitional or 94 migration path, to the country of arrival (host country) 3, 4 . 95
3) Consideration of the policies, practices and patient experiences along the cascade of care from 96 prevention to diagnosis and treatment of TB. 97
Mapping the existing country context along these axes may systematically identify research gaps and 98 priorities that are context specific. We describe potential research questions that can be derived within 99 classical research categories using this conceptual framework. 100
101
Epidemiologic Research 102
Despite a growing body of literature on the epidemiology of infectious diseases among migrants, critical 103 evidence gaps remain. This section addresses the various risks of TB in migrants along the spectrum of 104 the migration pathway, and how existing TB surveillance and data analysis systems may be mobilized to 105 answer specific research questions. Considering TB burden in low-, medium-, and high-incidence 106 countries, key epidemiological questions emerge. 107
108
First, what are the specific effects of migration on TB: is migration a risk for TB, or a risk of poor outcome, 109 or a mixture of these and others? There is substantial evidence that being a migrant from a high-or 110 medium-burden country is a risk factor for TB in foreign-born persons living in a low-TB incidence 111 country 3, 6 , but how migration changes that risk still remains unclear. A better understanding of TB risks associated with migration would help shaping appropriate multi-130 sectoral policies (before, during, and after migration) to improve TB prevention and care in these 131 populations. This is especially critical in low-incidence countries with a concentrated TB epidemic where 132 the majority of TB cases are among the non-native born population. It is also relevant for high TB burden 133 countries with a large number of migrants from other high burden countries, 4,11 an often overlooked 134 migration pathway. 135
136
Research is also needed to better understand TB transmission along migration routes whether migrant-to-137 migrant transmission or migrant-to-native population transmission. The limited and heterogeneous 138 existing data from molecular epidemiology do not provide enough evidence to measure the latter 3, 12 . 139
Moreover, findings can be hard to generalize, since transmission rates depend not only on the underlying 140 risk in a migrant group but also on existing TB care and prevention strategies in a given setting and mixing 141 patterns between the migrant and native population. Epidemiological research, including molecular 142 epidemiology combined with health systems research may help identify gaps and opportunities for 143 prevention of TB transmission. In this respect, careful attention should be paid to multi-drug resistant TB 144 (MDR-TB) in migrants and research should be conducted to better characterize the burden of drug 145 resistance in this population and its determinants 13, 14 . 146
147
The process of migration itself can have an impact on the relevance of TB-related policies, practices, and 148 patient experiences. It is therefore critical to design and expand TB surveillance systems to monitor TB 149 trends in different groups of migrants. Most countries that monitor TB rates in migrants lack detailed 150 information about type of migrant, migration routes, time since arrival and risk profile 3, 7 . Such 151 surveillance could inform more appropriate strategies for targeted testing and treatment of migrants with 152 higher TB risk. This type of research can inform migrant-inclusive patient pathways of care as a first step 153 in understanding migration specific gaps in health access, utilization, and health outcomes. 154
155
Guidance exists on how to collect migrant-inclusive epidemiologic data. However, research is needed to 156 assess the effectiveness of this type of guidance in resolving gaps in data and improving overall data 157 management and quality. The ECDC, for example, has developed guidance for the collection of TB risk 158 factor data as part of routine surveillance 15 . As the majority of TB cases among migrants arise from 159 reactivation of latent TB infection (LTBI) contracted in the country of origin 3 , there is a need to collect 160 high quality data on prevalence of LTBI in different migrant risk groups, and link these to TB register 161 data in order to determine reactivation rates and to identify additional determinants of disease. These types 162 of additional surveillance components require additional health systems research. OR/IR can then be used 163 to develop targeted interventions to reduce the higher risk of reactivation in these groups. 164
Operational and Implementation Research on the Patient Cascade of Care: Prevention, Diagnosis, 165 and Treatment of TB 166
Migrants from TB endemic countries are the largest TB risk group in a growing number of low-incidence 167 countries and therefore require special attention when designing TB prevention and care activities 3 . 168
Presently there is little consensus on the best interventions to target these populations, and there are limited 169 data on the implementation of evidence-based guidelines on management of TB in migrant settings [16] [17] [18] [19] . 170
This may be due to the highly variable environments, conditions, and causes of migration that make 171 standardized approaches challenging. Ensuring quality TB care (for active disease and latent infection) 172 for migrants requires appropriate OR/IR at every stage of the patient cascade of care to understand how 173 to optimize conditions for prevention, diagnosis, and treatment in each context 11, 20 . In this section, we 174 focus on potential OR/IR categorized by each step in the patient cascade of care, with a focus on policies 175 and programmatic practices relevant to prevention, diagnosis, and treatment of TB. 176
TB Diagnosis: Intertwining of Latent and Active Disease 177
Novel tools are needed to diagnose TB in general populations and differentiate the various stages of 178 infection 21 . Especially in very mobile migrant populations, diagnostic tests need to be of high 179 performance, easily operational, rapid and at the point of care so as to minimize losses to follow up. While 180 these characteristics certainly apply to the diagnosis of active disease (drug susceptible or drug resistant), 181 new programmatic strategies should be developed for diagnosis of latent TB infection (LTBI on the ability of migrants to access care when they experience symptoms and signs of TB along the 241 migration pathway. Studies from several EU host countries showed that access to medical services may 242 be restricted 44, 45 , and often depends on the type of residence permit the migrant holds 46 . Since access to 243 health care is essential for early diagnosis and treatment of TB, identifying the gaps and testing 244 interventions that can improve access to health services for all types of migrants is needed, particularly 245 for implementing quality TB care. For example, while it was shown using mathematical models that 246 screening high risk subpopulations with IGRAs had the potential for high cost effectiveness which was 247 conducive to policy change, lack of empirical effectiveness data in these subpopulations was identified as 248 a barrier to effective implementation of a targeted testing and treatment strategy 47 . 249
250
Migrants with TB often have lower treatment success rates compared to native individuals [48] [49] [50] [51] . 251
Understanding the underlying reasons for this is critical and context-specific. Several studies have shown 252 that even at the subnational level, identifying and targeting factors associated with default or loss to follow 253 up can improve health systems responses to TB treatment provision for migrant populations 49, 50, 52 . For 254 instance, a systematic review evaluating reasons for non-adherence to treatment in 5 continents described 255 heterogeneous TB treatment outcomes among migrants due to variability in legal status and social risk 256 factors such as education, employment and access to care 53 . This heterogeneity may be particularly 257 important when evaluating the full potential of novel treatment strategies such as short-course treatment 258 regimens for drug resistant disease, the use of digital health technologies to support treatment adherence 54, 259 55 , and planning for scale-up of treatment programs 53 . The critical point is that context-specific data are 260 required to understand how best to support migrants in initiating and completing treatment. Such evidence 261 can then expand to health systems research and policy change for creating mechanisms and application of 262 legal frameworks for cross-border TB control that facilitate access to care. 263
Social Protection Research 264
The majority of migrants are exposed to socioeconomic vulnerabilities along the migration pathway from 265 country of origin to country of destination, including those associated with 3 : 266 1) social, biological, and structural determinants of TB in their country of origin, in transit, and in 267 host country; 268 2) the migration process/transit (malnutrition, trauma, violence, mental health issues, substance 269 abuse, including alcohol and smoking); 270
3) the living conditions in the country of transit/destination (poor housing quality, crowding, 271 inadequate working conditions, poor nutrition, food insecurity); and 272 4) the limited access to health care services both during transit and in the country of destination, 273 often due to language, economic and cultural barriers. 274
All these features of poverty and vulnerability point to substantial needs for social protection, defined as 275 a set of policies and programmes aimed at reducing the social and economic risk for those who need to 276 access and receive care 10 . 277
Social protection strategies have shown promise as a way to improve treatment outcomes among TB 278 affected households with significant socioeconomic risk 56, 57 . However, even in settings where social 279 protection schemes have shown benefit in TB outcomes, operationalizing these strategies in migrants 280 may pose significant challenges 58 . Research is required that systematically assesses migrants' 281 vulnerabilities and their social and economic barriers to care to identify where and when in the migration 282 pathway social protection interventions should be deployed. Understanding and evaluating the benefit 283 of TB-sensitive approaches (social protection schemes for which TB patients may be eligible based on 284 criteria unrelated to their disease) versus TB-specific approaches (social protection schemes for with TB 285 disease is an eligibility criteria) will be required in understanding how to operationalize these 286 interventions. These vulnerabilities as well as barriers to care are unlikely to be significantly different 287 from those observed among non-migrant populations when accounting for socioeconomic status, but 288 migration is likely to exacerbate them. Research is required to understand the full effect of this 289 potentiation and identify suitably targeted social protection interventions. 290
Despite a growing body of evidence that suggests the positive impact of cash transfer schemes on TB 291 and economic outcomes 57, 59-61 , we are not aware of such studies among migrants 62 . While health 292 policies in some countries include access to social protection for any legal resident, there is limited 293 information on how such effective policies may translate to migrant populations with similar 294 socioeconomic characteristics but without a legal status 56, 61, 62 . Research on how to operationalize social 295 protection and measure the effect of economic support and welfare 2, 63, 64 on TB outcomes in migrant 296 populations is needed to inform development of suitable social protection schemes both in high-and 297 middle-income host countries 65 . Examples of such research include studying the feasibility and impact 298 of a cash transfer for migrants diagnosed with TB or the impact of short-term disability insurance at the 299 time of treatment initiation. High-quality operational/implementation research on social protection that 300 includes migrants would contribute to reaching the targets of the End TB Strategy within the larger 301 context of the SDGs 66 . 302
303
Creating and Operationalizing a Migrant-Inclusive Research Agenda 304
While high-and medium-burden countries are developing national TB research agendas in keeping with 305 Pillar 3 of the End TB Strategy, very few, if any, specifically address the particular challenges of TB 306 prevention and care in migrants. To properly inform national and international policies to improve 307 migrants' health with particular reference to TB, a research agenda is needed at the global and country 308 level that: (i) draws from a context-specific and migrant-inclusive situational assessment; (ii) engages a 309 variety of partners including those from migrant communities; (iii) leverages supranational or regional 310 networks; (iv) draws on political leadership; and (v) includes ethical and accountable mechanisms for 311 implementation and dissemination. 312
The research and innovation pillar of the End TB Strategy 2 promotes the need for well-designed and 313 empirically grounded research. To facilitate this, WHO has developed the Global Action Framework for 314
TB Research
67 and a Toolkit 68 for developing national TB research agendas. These tools may be used to 315 develop context-specific research questions related to the challenges of eliminating TB in migrant 316 populations and to ensure that the national TB research agendas being developed are migrant-inclusive. 317
Such research agendas will benefit from engaging stakeholders with expertise in migration, epidemiology, 318 demography, biomedicine, health systems, and other social sciences in the identification of research 319 priorities to improving the health of the migrant population. The participation of the migrant community 320 is necessary to guarantee the proper consideration of the migrant perspective -for example, in addressing 321 the impacts of migrant/refugee status, ethnicity and socioeconomic status on health service access and 322
utilization. 323
Countries establishing migrant-inclusive TB research agendas should consider multi-country agreements 324 that harmonize research priorities, such as between migrants' countries of origin and destination (both 325 high and low TB burden countries). This can be achieved through national or regional TB and migration 326 research platforms that would allow for transnational linkages critical for building capacity and 327 disseminating knowledge and innovation. Such platforms, or research "hubs", may be powerful in 328 monitoring TB control efforts in migrants, advocating for political and financial commitment, 329 strengthening institutional and community capacities and ensuring the collaboration necessary to address 330 this issue head on 11 . Political leadership is needed to prioritize an innovative TB response through an 331 integrated and multi-disciplinary research approach. 
Conclusion 346
Identifying and pursuing a migration-inclusive TB research agenda is critical for advancing our 347 understanding of TB among migrant populations and improving TB prevention and care worldwide. In 348 this review, we propose a conceptual framework for constructing migrant-inclusive research agendas at 349 national and multi-national levels, and present areas of particular focus for research in countries attempting 350 to address TB diagnosis, treatment and prevention in migrant populations (Table) 
